<?xml version="1.0" encoding="utf-8" standalone="no"?>
<!DOCTYPE file
  SYSTEM 'wikixml.dtd'>
<file type="Article" date="2024-10-22T16:20:04Z" sourceCorpus="COVID-19" filename="67055625" title="ARCT-021" url="https://en.wikipedia.org/wiki/ARCT-021">
	<text>
		<segment id="id67055625">Arcturus COVID-19 vaccine


ARCT-021, also known as LUNAR-COV19, is a COVID-19 vaccine candidate developed by Arcturus Therapeutics.

 Medical uses 
It requires the intramuscular injection with a single dose.

 Pharmacology 
ARCT-021 is an self-amplifying mRNA vaccine.

 History 
Arcturus Therapeutics partnered with Singapore's Dukeâ€“NUS Medical School to develop a COVID-19 vaccine. The company also partnered with Catalent, a contract development and manufacturing organization, to manufacture multiple batches of Arcturus' COVID-19 mRNA vaccine candidate.

 Clinical trials 
LUNAR-COV19 clinical trials in humans began in July 2020. On 4 January 2021, Arcturus Therapeutics started Phase-2 clinical trials.

 Economics 
Arcturus has entered into development and supply agreements with the Economic Development Board of Singapore and supply agreements with the Israel Ministry of Health for LUNAR-COV19.

 References 


 External links 













</segment>
	</text>
</file>
